Wiley Matthew T. — SEC Form 4 filings
SEC reporting owner CIK 1759703. 12 Form 4 filings on record with FilingPulse; latest filed 2026-09-14.
Transaction summary — filings shown
Covers all 12 filings on record, filed 2024-04-08 to 2026-09-14. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 5 legs across 5 filings — 10,606 shares, $135,663 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 14.
- Largest priced transaction: sale of 2,867 shares @ $45.03 ($129,101) in Definium Therapeutics, Inc., filed 2026-06-26.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Definium Therapeutics, Inc. (DFTX) | Chief Commercial Officer | 6 | — | 1 leg · 2,867 sh · $129,101 | 5 |
| BioXcel Therapeutics, Inc. (BTAI) | — | 6 | — | 4 legs · 7,739 sh · $6,562 | 9 |
Form 4 filings — Wiley Matthew T.
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-09-14 | 4 | Definium Therapeutics, Inc. (DFTX) | Grant/award (A): 125,000 @ $0 | EDGAR |
| 2026-08-12 | 4 | Definium Therapeutics, Inc. (DFTX) | Grant/award (A): 62,500 @ $0 | EDGAR |
| 2026-06-26 | 4 | Definium Therapeutics, Inc. (DFTX) | Sale (S): 2,867 @ $45.03 | EDGAR |
| 2026-06-22 | 4 | Definium Therapeutics, Inc. (DFTX) | Grant/award (A): 62,500 @ $0 | EDGAR |
| 2026-02-05 | 4 | Definium Therapeutics, Inc. (DFTX) | Grant/award (A): 115,000 @ $0 | EDGAR |
| 2025-04-01 | 4 | BioXcel Therapeutics, Inc. (BTAI) | Grant/award (A): 1,875 (derivative) @ $0 | EDGAR |
| 2025-03-18 | 4 | Mind Medicine (MindMed) Inc. (MNMD) | Grant/award (A): 350,000 (derivative) @ $0 | EDGAR |
| 2024-10-03 | 4 | BioXcel Therapeutics, Inc. (BTAI) | Grant/award (A): 21,250 · Sale (S): 6,272 @ $0.55 | EDGAR |
| 2024-09-17 | 4/A | BioXcel Therapeutics, Inc. (BTAI) | Option exercise (M): 750 (derivative) @ $0 | EDGAR |
| 2024-09-17 | 4 | BioXcel Therapeutics, Inc. (BTAI) | Option exercise (M): 750 · Sale (S): 215 @ $0.69 · Option exercise (M): 750 (derivative) @ $0 | EDGAR |
| 2024-06-18 | 4 | BioXcel Therapeutics, Inc. (BTAI) | Option exercise (M): 750 · Sale (S): 244 @ $1.26 · Option exercise (M): 750 (derivative) @ $0 | EDGAR |
| 2024-04-08 | 4 | BioXcel Therapeutics, Inc. (BTAI) | Option exercise (M): 3,000 · Sale (S): 1,008 @ $2.64 · Option exercise (M): 3,000 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1759703 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →